NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
University of California, San Diego
Boehringer Ingelheim
CRISPR Therapeutics
Hoffmann-La Roche
Laval University
HiberCell, Inc.
Sichuan University
Boston Scientific Corporation
Intensity Therapeutics, Inc.
Sirtex Medical
BeiGene
Imunon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Kyowa Kirin Co., Ltd.
UNICANCER
Celgene
MedImmune LLC
Chinese University of Hong Kong
Cantargia AB
Universitaire Ziekenhuizen KU Leuven
Ohio State University Comprehensive Cancer Center
Centre Hospitalier Universitaire de Nice
H. Lee Moffitt Cancer Center and Research Institute
Eisai Inc.
Akamis Bio
H. Lee Moffitt Cancer Center and Research Institute
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Daiichi Sankyo
Hospices Civils de Lyon
Pfizer
Medical College of Wisconsin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eisai Inc.
Eisai Inc.
Onkovis GmbH
Washington University School of Medicine
Norwegian Department of Health and Social Affairs
Onkovis GmbH
The Royal Bournemouth Hospital
Washington University School of Medicine
University of Pittsburgh
Yale University
Novartis
Merck KGaA, Darmstadt, Germany
Bayer
Novartis
Eastern Hepatobiliary Surgery Hospital
Samsung Medical Center
Stanford University